Chemotherapy and skin reactions

Journal of Experimental & Clinical Cancer Research

Giuseppe Monfrecola¹  Dario Bianca¹  Luigia Panariello¹  Maria Mariano³  Maria Concetta Romano²  Norma Cameli³  Gabriella Fabbrocini¹ 

[1] Division of Clinical Dermatology, Department of Systematic Pathology, University of Naples Federico II, Via Sergio Pansini 5, 80133, Naples, Italy;ASL ROMA C - School of University Tor Vergata, Rome, Italy;San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy

关键词: Paronychia;    Xerosis;    Anti-EGF;    Follicular rash;    Skin toxicity;    Chemotherapy;   

Others  :  826383
DOI  :  10.1186/1756-9966-31-50

 received in 2012-02-07, accepted in 2012-05-28,  发布年份 2012

【 摘 要 】

Background

New chemotherapic agents and new protocols in oncology have led to an increasing survival rate in patients affected by tumors. However, this increased use has been accompanied by a growth in the incidence of cutaneous side effects and a worsening of patients’ quality of life. Appropriate management of skin toxicity associated with chemotherapic agents is therefore necessary for suitable drug administration and to improve quality of life and clinical outcomes.

Methods

We have clinically examined 100 patients affected by cancer, determining type, frequency, treatment, and evolution of side effects related to chemotherapy.

Results

The prevalent cutaneous side effects in patients undergoing chemotherapy are skin rash, xerosis, pruritus, paronychia, hair abnormality, and mucositis. The clinical cases are reported in detail.

Conclusion

Oncological therapies have become more selective and have low systemic toxicity because of their high specificity, but cutaneous side effects are common and may worsen the quality of life of these patients.

【 授权许可】

   
2012 Fabbrocini et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Noushin H, Haley N, Susan B: Chemiotheraputic agents and the skin: an update. J Am Acad Dermatol 2008, 58:545-570.
• [2]Tianhong L, Roman P: Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol 2009, 4:107-119.
• [3]Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwerkerkb J, Gelderblomb H: Classification and management of skin, hair and nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007, 43:845-851.
• [4]Jatoi A, Nguyen PL: Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008, 13:1201-1204.
• [5]Wagner LI, Lacouture ME: Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 2007, 21:34-36.
• [6]U. S. Department of Health and Human Services: Common terminology criteria for adverse events (CTCAE) version 4.03. 2010, :.
• [7]Lacouture ME: The growing importance of skin toxicity in EGFR inhibitor therapy. Oncology (Williston Park) 2009, 23:194-196.
• [8]Pérez-Soler R: Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003, 17:23-28.
• [9]Vasquez-Bayo C, Rodriguez-Bujaldon AL, Jimenez-Puya R, Galàn-Gutierrez M, Moreno-Gimenez JC: Capecitabine induced hyperpigmentation. Actas Dermosifiliogr 2007, 98:491-493.
• [10]Milano G, Etlenne-Grimaldi MC, Marl M, Lasalle S, Formento JL, Francoual M, et al.: Candidate mechanisms for capecitabine related hand-foot syndrome. Br J Clin Pharmacol 2008, 66:188-95.
• [11]Dave S, Thappa DM: Peculiar pattern of nail pigmentation following cyclophosphamide therapy. Dermatol Online J 2003, 9(3):14.
• [12]Kumar S, Dixit R, Karmakar S, Paul S: Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen. Indian J Pharmacol August, 42(4):243-244.
• [13]Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, et al.: Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with Sorafenib. The Oncologist 2010, 15:85-92.
• [14]Williams V, Cohen P, Stewart D: Sorafenib-induced premalignant and malignant skin lesions. Int J Dermatol 2011, 50(4):396-402.
• [15]Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, et al.: Hypertension and hand-foot skin reaction related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010, 29:95. BioMed Central Full Text